Karo Healthcare AB Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Karo Healthcare AB Stock Forecast and Price Target
Karo Healthcare AB has an average price target of kr0.00 recently offered by notable experts for 2024, which would represent a potential downside of approximately 0 from the last closing price in November, 2022 if reached. This potential increase is based on a high estimate of kr0.00 and a low estimate of kr0.00. If you're thinking of investing in KARO stock, it's critical to check out its competitors as well.
N/A
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr281.00 | Buy/Sell | kr293.00 | 13.88% |
| VITR Stock Forecast | Vitrolife AB (publ) | Buy |
18
|
kr163.30 | Buy/Sell | kr250.00 | 34.72% |
| BIOA B Stock Forecast | BioArctic AB (publ) | Outperform |
10
|
kr197.50 | Buy/Sell | kr372.40 | 77.22% |
| GENO Stock Forecast | Genovis AB (publ.) | Outperform |
16
|
kr28.50 | Buy/Sell | kr75.67 | 77.19% |
| VICO Stock Forecast | Vicore Pharma Holding AB (publ... | Buy |
4
|
kr17.30 | Buy/Sell | kr70.75 | 275.72% |
Karo Healthcare AB Revenue Forecast for 2023 - 2025 - 2030
Karo Healthcare AB's Revenue has grown In the last two years, rising from kr2.88B to kr4.14B – a growth of 43.55%. In the following year, the 0 analysts surveyed believe that Karo Healthcare AB's Revenue will decrease by 19.84%, reaching kr3.32B. According to professionals, by 2030, Karo Healthcare AB's Revenue will have decreased by 17.81%, falling down to kr3.40B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HNSA Stock Forecast | Hansa Biopharma AB (publ) | Buy |
6
|
kr27.32 | Buy/Sell | kr123.00 | 244.07% |
| BINV Stock Forecast | BioInvent International AB (pu... | Outperform |
10
|
kr25.15 | Buy/Sell | kr107.00 | 230.02% |
| XSPRAY Stock Forecast | Xspray Pharma AB (publ) | Outperform |
6
|
kr40.45 | Buy/Sell | kr120.00 | 164.52% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMMNOV Stock Forecast | Immunovia AB (publ) | - |
0
|
kr1.94 | Buy/Sell | kr0.00 | -100.00% |
| ATORX Stock Forecast | Alligator Bioscience AB (publ) | Outperform |
0
|
kr0.93 | Buy/Sell | kr1.83 | 147.31% |
| CANTA Stock Forecast | Cantargia AB (publ) | Buy |
5
|
kr3.45 | Buy/Sell | kr13.67 | 276.81% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XBRANE Stock Forecast | Xbrane Biopharma AB (publ) | Outperform |
5
|
kr0.21 | Buy/Sell | kr116.00 | 200.00% |
| IMMU Stock Forecast | Mendus AB (publ) |
9
|
kr0.47 | Buy/Sell | kr1.70 | 282.98% | |
| ACE Stock Forecast | Ascelia Pharma AB (publ) |
0
|
kr11.16 | Buy/Sell | kr19.50 | -12.63% |
Karo Healthcare AB EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Karo Healthcare AB's EBITDA has decreased by 9.10%, from kr789.59M to kr717.76M. In the next year, analysts predict that EBITDA will jump to kr743.65M – up 3.61% from the current level. Looking ahead to eight years, experts forecast that EBITDA will grow by 3.64%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| KDEV Stock Forecast | Karolinska Development AB (pub... |
8
|
kr1.57 | Buy/Sell | kr4.70 | 157.96% | |
| ISR Stock Forecast | ISR Immune System Regulation H... | - |
0
|
kr7.43 | Buy/Sell | kr0.00 | -100.00% |
| HAMLET B Stock Forecast | Hamlet BioPharma AB (publ) | - |
0
|
kr2.35 | Buy/Sell | kr0.00 | -100.00% |
Karo Healthcare AB EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Karo Healthcare AB's EBIT has fallen from kr313.18M to kr-71.17M – a 122.72% decrease. Analysts predict that Karo Healthcare AB's EBIT will increase in the upcoming year, reaching kr-264.98M. This would represent an increase of 272.32%. Over the next eight years, experts predict that Karo Healthcare AB's EBIT will grow at a rate of 891.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ONCO Stock Forecast | Oncopeptides AB (publ) |
0
|
kr2.96 | Buy/Sell | kr6.90 | 116.22% | |
| GUARD Stock Forecast | Guard Therapeutics Internation... |
8
|
kr29.80 | Buy/Sell | kr0.23 | 118.12% | |
| IVACC Stock Forecast | Intervacc AB (publ) |
10
|
kr4.18 | Buy/Sell | kr27.00 | 91.39% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SYNACT Stock Forecast | SynAct Pharma AB | - |
7
|
kr7.05 | Buy/Sell | kr15.00 | -100.00% |
| NICA Stock Forecast | Nanologica AB (publ) |
0
|
kr5.50 | Buy/Sell | kr14.75 | 118.18% | |
| CLBIO Stock Forecast | Corline Biomedical AB |
6
|
kr10.30 | Buy/Sell | kr35.00 | 210.68% |
.jpg)